Steven A. Rosenberg, M.D., Ph.D.
Steven A. Rosenberg, M.D., Ph.D.
Chief
Senior Investigator
Head, Tumor Immunology Section

Dr. Rosenberg pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients.

As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer

Areas of Expertise
1) cancer immunotherapy 2) tumor-infiltrating lymphocytes 3) cancer antigens 4) T cell receptors 5) metastatic melanoma 6) gene therapy

Contact Info

Steven A. Rosenberg, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3940
Bethesda, MD 20892-1201
Ph: 301-496-4164
SAR@nih.gov

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology
  1. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA
    Nat Med. 22(4): 433-8, 2016.
  2. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA
    Science. 350(6266): 1387-90, 2015. [ Journal Article ]
  3. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
    Science. 344: 641-5, 2014. [ Journal Article ]
  4. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA
    Nat Med. 19: 747-752, 2013. [ Journal Article ]
  5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME
    Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Name Position
Ph.D. Research Fellow
Mojgan Ahmadzadeh Ph.D. Research Fellow (Contr)
Harris Akhtar Postbaccalaureate Fellow
Gal Cafri Ph.D. Postdoctoral Fellow (Visiting)
Pearl Chapman Secretary (Contr)
Samuel Chatmon Biologist
David N. Danforth Jr., M.S., M.D. Staff Clinician
Drew Deniger Ph.D. Postdoctoral Fellow (CRTA)
Arash Eidizadeh Postbaccalaureate Fellow
Jared Gartner Research Biologist
Stephanie L. Goff, M.D. Staff Clinician
Alena Gros Ph.D. Research Fellow
Sadia Ilyas M.D. Clinical Fellow
Santhosh Karunakaran Senior IND Manager (Contr)
Jae Ho Kim Postbaccalaureate Fellow
Arati Klamath Research Specialist (Contr)
Isaac Kriley M.D. Clinical Fellow
Almin Lalani Ph.D. Postdoctoral Fellow (CRTA)
Vid Leko M.D. Clinical Fellow
Yong-Chen Lu Ph.D. Postdoctoral Fellow (Visiting)
Parisa Malekzadeh M.D. Clinical Fellow
Deepti Marshall Patient Care Coordinator (Contr)
Lucas McDuffie M.D. Clinical Fellow
Debbie Nathan R.N. Clinical Research Nurse
Lien T. Ngo Research Biologist
Anna Pasetto Ph.D. Postdoctoral Fellow (Visiting)
Todd Prickett Ph.D. Research Fellow
Satyajit Ray Ph.D. Research Biologist
Richard M. Sherry, M.D. Staff Clinician
Mary Ann Toomey R.N. Clinical Research Nurse
Eric Tran Ph.D. Postdoctoral Fellow (Visiting)
Katarzyna Trebska-McGowan M.D. Clinical Fellow
Tyler Willett Postbaccalaureate Fellow
Rami Yoseph Ph.D. Postdoctoral Fellow (Visiting)
Nikolaos Zacharakis Research Fellow
Zhili Zheng Research Biologist

Clinical Trials

Research

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology

Publications

  1. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA
    Nat Med. 22(4): 433-8, 2016.
  2. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA
    Science. 350(6266): 1387-90, 2015. [ Journal Article ]
  3. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
    Science. 344: 641-5, 2014. [ Journal Article ]
  4. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA
    Nat Med. 19: 747-752, 2013. [ Journal Article ]
  5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME
    Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]

Biography

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Team

Name Position
Ph.D. Research Fellow
Mojgan Ahmadzadeh Ph.D. Research Fellow (Contr)
Harris Akhtar Postbaccalaureate Fellow
Gal Cafri Ph.D. Postdoctoral Fellow (Visiting)
Pearl Chapman Secretary (Contr)
Samuel Chatmon Biologist
David N. Danforth Jr., M.S., M.D. Staff Clinician
Drew Deniger Ph.D. Postdoctoral Fellow (CRTA)
Arash Eidizadeh Postbaccalaureate Fellow
Jared Gartner Research Biologist
Stephanie L. Goff, M.D. Staff Clinician
Alena Gros Ph.D. Research Fellow
Sadia Ilyas M.D. Clinical Fellow
Santhosh Karunakaran Senior IND Manager (Contr)
Jae Ho Kim Postbaccalaureate Fellow
Arati Klamath Research Specialist (Contr)
Isaac Kriley M.D. Clinical Fellow
Almin Lalani Ph.D. Postdoctoral Fellow (CRTA)
Vid Leko M.D. Clinical Fellow
Yong-Chen Lu Ph.D. Postdoctoral Fellow (Visiting)
Parisa Malekzadeh M.D. Clinical Fellow
Deepti Marshall Patient Care Coordinator (Contr)
Lucas McDuffie M.D. Clinical Fellow
Debbie Nathan R.N. Clinical Research Nurse
Lien T. Ngo Research Biologist
Anna Pasetto Ph.D. Postdoctoral Fellow (Visiting)
Todd Prickett Ph.D. Research Fellow
Satyajit Ray Ph.D. Research Biologist
Richard M. Sherry, M.D. Staff Clinician
Mary Ann Toomey R.N. Clinical Research Nurse
Eric Tran Ph.D. Postdoctoral Fellow (Visiting)
Katarzyna Trebska-McGowan M.D. Clinical Fellow
Tyler Willett Postbaccalaureate Fellow
Rami Yoseph Ph.D. Postdoctoral Fellow (Visiting)
Nikolaos Zacharakis Research Fellow
Zhili Zheng Research Biologist